<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Emerging data suggest that in the current era of modern systemic therapies, resection of colorectal <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> with concomitant extrahepatic disease may be a curative option in selected patients </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: A commentary of several key recent papers including an international multi-institutional registry study may provide directions in the future management of this disease entity </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: The premise of selecting patients for a surgical approach to resect colorectal <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> and concomitant extrahepatic disease should be individualized </plain></SENT>
<SENT sid="3" pm="."><plain>Incorporation of key prognostic factors that include the site of extrahepatic disease, the ability to undertake a complete resection, disease responding to chemotherapy, and an assessment of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> biology through examining an individual's disease history may guide the selection of suitable patients for this therapeutic pursuit </plain></SENT>
<SENT sid="4" pm="."><plain>A 5-year survival of 30% may be realized in well-selected patients </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSION: Concomitant extrahepatic disease in patients with colorectal <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> should not be a contraindication to resection of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> </plain></SENT>
</text></document>